|

Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients

RECRUITINGN/ASponsored by University Hospital, Alexandroupolis
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Alexandroupolis
Started2025-03-10
Est. completion2026-03-10
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06929507

Summary

This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration. It is known that previous anti-VEGF agents has systematic absorption and may cause deterioration in renal function of the patients. However, the effect of Faricimab on kidney function has not been investigated yet. Taking into account that Ang-2 has destructive effect on kidneys, the investigation of the effect of its inhibition in diabetic patients who have already renal function deterioration may provide a valuable information in scientific community.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients with diabetes
* Patients with DME or nAMD or macular edema secondary to retinal vein occlusion
* Patients already receiving nephroprotective drugs

Exclusion Criteria:

* Patients with end stage renal disease
* Pregnancy
* Patients with other retinal disorders
* Previous renal transplantation Patients under hemodialysis

Conditions4

DiabetesDiabetic Macular Edema (DME)Neovascular Age Related Macular DegenerationRenal Function Disorder

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.